Literature DB >> 7539659

CD34-positive early stages of human T-cell differentiation.

C Schmitt1, S Ktorza, S Sarun, M P Verpilleux, C Blanc, M A Deugnier, A Dalloul, P Debré.   

Abstract

Thymus, the main organ for T lymphopoiesis, requires a permanent influx of progenitors from bone marrow (BM) or fetal liver. An essential question relating to early T-cell development is the identification of the progenitor population which actually homes to the thymus. Recent findings have shown that human multipotent progenitor/stem cells expressing CD34 have the capacity to differentiate into T cells when introduced into a thymic environment. More mature CD34+ bone marrow cells coexpressing CD7 and having a poor myeloid differentiation capacity can also efficiently differentiate into T cells in vitro. These lymphoid committed precursors might be the true thymic repopulating cells. In the thymus, cells with a similar CD34+7+ phenotype include the most primitive thymocyte precursors. CD34+ thymocytes have no myeloid differentiation potential, but may include precursors for natural killer (NK) cells. Interleukin-7 (IL7) is a potent in vitro growth factor for CD34+ thymocytes. Whereas current data do not support a crucial role for IL2, patients with IL2 receptor gamma chain (IL2R gamma) deficiency lack T- and NK cells. The recent demonstration that IL2R gamma is part of the receptor for IL7 strongly suggests that this cytokine plays an essential role in in vivo T lymphocyte and NK development.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539659     DOI: 10.3109/10428199509051702

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Expression of CD10 on lymphoid cells associated with thymoma.

Authors:  J Nakajima; S Takamoto; T Kohno; T Ohtsuka; J Matsumoto
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-02

2.  A simple model system enabling human CD34(+) cells to undertake differentiation towards T cells.

Authors:  Antonio Lapenna; Christopher B-Lynch; Chrysa Kapeni; Richard Aspinall
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.